Last reviewed · How we verify
ANT-1207
ANT-1207 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
ANT-1207 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | ANT-1207 |
|---|---|
| Sponsor | Anterios Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, ANT-1207 reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis (PHASE2)
- Clinical Trial To Evaluate ANT-1207 In Subjects With Acne (PHASE2)
- Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANT-1207 CI brief — competitive landscape report
- ANT-1207 updates RSS · CI watch RSS
- Anterios Inc. portfolio CI